Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain

Jensen, Karin B.a; Kosek, Evaa; Petzke, Frankb; Carville, Serenac; Fransson, Petera; Marcus, Hankeb; Williams, Steven C.R.c; Choy, Ernestc; Giesecke, Thorstenb; Mainguy, Yvesd; Gracely, Richarde; Ingvar, Martina,*

doi: 10.1016/j.pain.2009.03.018

ABSTRACT Over the years, many have viewed Fibromyalgia syndrome (FMS) as a so-called “functional disorder” and patients have experienced a concomitant lack of interest and legitimacy from the medical profession. The symptoms have not been explained by peripheral mechanisms alone nor by specific central nervous system mechanisms. In this study, we objectively evaluated the cerebral response to individually calibrated pain provocations of a pain-free body region (thumbnail). The study comprised 16 female FMS patients and 16 individually age-matched controls. Brain activity was measured using functional magnetic resonance imaging (fMRI) during individually calibrated painful pressures representing 50 mm on a visual analogue scale (VAS) ranging from 0 to 100 mm. Patients exhibited higher sensitivity to pain provocation than controls as they required less pressure to evoke equal pain magnitudes (UA = 48, p < .002). Despite lower pressures applied in patients at VAS 50 mm, the fMRI-analysis revealed no difference in activity in brain regions relating to attention and affect or regions with sensory projections from the stimulated body area. However, in the primary link in the descending pain regulating system (the rostral anterior cingulate cortex) the patients failed to respond to pain provocation. The attenuated response to pain in this brain region is the first demonstration of a specific brain region where the impairment of pain inhibition in FMS patients is expressed. These results validate previous reports of dysfunctional endogenous pain inhibition in FMS and advance the understanding of the central pathophysiologic mechanisms, providing a new direction for the development of successful treatments in FMS.

aStockholm Brain Institute, Osher Center for Integrative Medicine, Karolinska Institutet, Stockholm, Sweden

bUniversity Hospital of Cologne, Cologne, Germany

cKings College London, London, UK

dPierre Fabre Médicament, Labège, France

eUniversity of Michigan, Ann Arbor, USA

*Corresponding author. Tel.: +46 851775134.



Article history:

Received August 15, 2008

Received in revised form March 16, 2009

Accepted March 20, 2009.

© 2009 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website